aibioInnovent Biologics
Innovent Biologics is a Hong Kong-listed Chinese drugmaker that sells 20 medicines in China, including the cancer drug sintilimab and the obesity and diabetes drug mazdutide, and develops new cancer and chronic disease drugs with global partners.
- Ticker
- 1801
- Listing
- HKEX, China
- Next date
- October 23, 2026
- Chief executive
- Dr. De-Chao Michael Yu, Founder, Chairman and CEO
Desk view · Opinion · Updated Oct 22, 2026
Innovent is profitable at home. IBI363 decides its global story
Innovent has become a profitable Chinese drug company with fast sales growth and a large cash pile. Its upside beyond China rests on IBI363 and arcotatug tavatecan, which still need global randomized wins. The balance sheet gives it time to find out.
Read the full desk viewaibio.space Investor Rank · Opinion
8/10 Positive view
Profitable in China with revenue up 44.8% and over RMB 30 billion in cash; global growth depends on IBI363 and arcotatug tavatecan winning randomized trials.
- Technology
- 2/2
- Odds
- 1/2
- Balance sheet
- 2/2
- Risk
- 1/2
- Momentum
- 2/2
Opinion only. The Investor Rank is aibio.space's opinion of the company's business position, drawn from the public sources on this page. It is not a recommendation to buy, sell or hold any security and it is not investment advice. It does not consider the share price, valuation or your circumstances, and it can change at any time. Payments from companies never affect it. How the rank works.
- Technology
- Broad and commercial. Innovent sells 20 products in China, and its CLDN18.2 drug met a phase 3 endpoint, though its biggest bet, IBI363, has only uncontrolled phase 1 data.
- Odds
- Mixed by asset. Arcotatug tavatecan is under priority review in China, while IBI363 must beat docetaxel in a global phase 3 in a setting where many drugs have failed.
- Balance sheet
- Strong and profitable. Cash was RMB 30.2 billion at July 31, 2026, and first-half IFRS profit rose 50.2% to RMB 1,253.1 million.
- Main risk
- Global proof is pending. The large partner deals pay mostly in milestones, and IBI363 carries a 64.9% rate of grade 3 or worse side effects at its higher dose.
- Watch next
- ESMO and melanoma. Gastric cancer phase 3 data come at ESMO on October 23, and the IBI363 melanoma readout is due by early 2027.
Top news on Innovent
Questions investors ask
What is aibio.space's Investor Rank for Innovent Biologics?
8 out of 10, our positive view. Profitable in China with revenue up 44.8% and over RMB 30 billion in cash; global growth depends on IBI363 and arcotatug tavatecan winning randomized trials. This is opinion only, not a recommendation to buy, sell or hold, and it does not consider the share price or valuation. Source
Is Innovent Biologics profitable?
Yes. Innovent reported IFRS profit of RMB 1,253.1 million for the first half of 2026, up 50.2%, after its first full-year profit in 2025. Source
What is IBI363?
IBI363 is a PD-1 blocker fused to an IL-2 arm biased toward the alpha receptor. It is in the global phase 3 MarsLight-11 trial against docetaxel in lung cancer that progressed after immunotherapy, co-developed with Takeda. Source
How much cash does Innovent have?
Innovent had cash on hand of RMB 30.2 billion, about US$4.5 billion, as of July 31, 2026. Source
What is arcotatug tavatecan?
It is Innovent's CLDN18.2-targeted antibody-drug conjugate, also called IBI343 or TAK-921. Its phase 3 G-HOPE-001 trial in previously treated gastric cancer met its primary endpoint and the China filing was accepted with priority review. Source
Who is Innovent's CEO?
Dr. De-Chao Michael Yu is Innovent's founder, chairman and chief executive officer, and holds both the chairman and CEO roles. Source
Where is Innovent Biologics headquartered?
SEC records list its business address as 120 BROADWAY, NEW YORK, NY, 10271. Source
Legal and investor matters
The 2025 annual report (published 2026-04-28) states: "The Company was not involved in any material litigation or arbitration during the year ended 31 December 2025." The 2026 interim report (published 2026-09-29) states the same for the six months ended 30 June 2026. Source
- Other
Innovent signs oncology collaboration with Pfizer, US$650 million upfront
On 2026-05-29 Innovent Biologics announced a global licensing and collaboration agreement with Pfizer covering 12 early-stage oncology programs, including antibody-drug conjugates and multi-specific antibodies. Innovent will receive a US$650 million upfront payment and is eligible for up to US$9.85 billion in milestones, for a total value of up to US$10.5 billion, plus royalties. Closing is subject to required regulatory approvals.
- Other
Innovent signs Lilly collaboration with US$350 million upfront
On 2026-02-08 Innovent Biologics announced a strategic collaboration with Eli Lilly in oncology and immunology, with a US$350 million upfront payment and milestones of up to about US$8.5 billion. The agreement became effective on 2026-03-24 after early clearance from the U.S. Federal Trade Commission. Innovent said on 2026-03-25 that media reports describing the effectiveness as an acquisition of the company were incorrect and that it was not pursuing such a transaction.
- Financing
Innovent issues 6,913,834 shares to Takeda at HK$112.56 as Takeda deal closes
On 2025-12-04 Innovent Biologics closed a share issuance to Takeda Pharmaceuticals International under its general mandate, allotting 6,913,834 shares at HK$112.56 per share, about 0.40% of the enlarged share capital. Gross proceeds were about HK$778 million. The issue was part of a collaboration announced on 2025-10-22 that carries a US$1.2 billion upfront payment including a US$100 million equity investment.
- Financing
Innovent places 55,000,000 new shares at HK$78.36, with net proceeds of about HK$4.27 billion
On 2025-06-26 Innovent Biologics agreed to place 55,000,000 new shares at HK$78.36 per share under its general mandate, about 3.33% of shares in issue. Net proceeds were about HK$4,265.4 million. The placing completed on 2025-07-04, with shares placed to not fewer than six independent placees.
- Other
Innovent says it knows of no inside information after unusual share movement
On 2025-01-16 Innovent Biologics issued a voluntary announcement saying it had noted unusual price and trading volume movements in its shares. After reasonable enquiries, the board said it was not aware of any information that needed to be disclosed to avoid a false market, or any inside information under the Securities and Futures Ordinance. The company said its business and operations remained unchanged.
- Other
Innovent grants Roche global rights to DLL3 ADC IBI3009 for US$80 million upfront
On 2025-01-02 Innovent Biologics announced a collaboration and exclusive license agreement with Roche for IBI3009, a DLL3-targeted antibody-drug conjugate for small cell lung cancer. Roche receives exclusive global rights to develop, manufacture and commercialize it. Innovent will receive an upfront payment of US$80 million and is eligible for milestone payments of up to US$1 billion plus tiered royalties.
Pipeline
| Program | Indication | Stage |
|---|---|---|
| IBI363 (TAK-928, PD-1/IL-2α-biased bispecific) | Immunotherapy-resistant squamous and non-squamous NSCLC; melanoma; colorectal cancer | Global phase 3 (MarsLight-11) with Takeda; China registrational melanoma study Source |
| Arcotatug tavatecan (IBI343/TAK-921, CLDN18.2 ADC) | Third-line CLDN18.2-positive gastric or gastroesophageal junction cancer; pancreatic cancer | NDA under NMPA priority review (accepted June 2026); phase 3 in pancreatic cancer Source |
| Mazdutide (GCG/GLP-1 dual agonist) | Weight management and type 2 diabetes | Approved in China; 9 mg weight management NDA under review Source |
| IBI324 (VEGF/ANG2) | Diabetic macular edema and wet AMD | Global phase 3 planned by partner Ollin in second half of 2026 Source |
| IBI3003 (GPRC5D/BCMA/CD3 trispecific) | Relapsed or refractory multiple myeloma | Phase 3 in China (first patient dosed June 2026); phase 1 in U.S. Source |
| SYCUME (teprotumumab N01, IGF-1R) | Thyroid eye disease, including inactive disease | Approved in China; phase 3 RESTORE-3 in inactive TED met primary endpoint Source |
Stock chart
SEC filings and registration
- SEC name
- Innovent Biologics Inc/ADR
- CIK
- 1774163
- US tickers
- IVBXF (OTC)
- Business address
- 120 BROADWAY, NEW YORK, NY, 10271
- Phone
- 212-238-3000
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction